Background: Dolutegravir (DTG)-based regimens are globally recommended as first-line antiretroviral therapy for people living with HIV (PLHIV), yet real-world evidence suggests variability in adverse drug events (ADEs). We synthesized available clinical and pharmacoepidemiological evidence to estimate the pooled prevalence and associated factors of ADEs among adults receiving DTG-based therapy. Methods: This systematic review and meta-analysis were registered in PROSPERO (CRD42023486384) and conducted following PRISMA 2020 guidelines. We searched major databases for observational studies reporting ADEs in adults on DTG-based regimens up to June 29, 2025. Two reviewers independently screened studies, extracted data, and assessed quality using the Newcastle–Ottawa Scale. Random-effects meta-analysis (DerSimonian–Laird) was used to estimate pooled prevalence. Heterogeneity was assessed using I2 and subgroup analyses by region and study design. Publication bias was evaluated using Egger’s and Begg’s tests. Findings: Twelve studies involving diverse geographic regions were included. The pooled prevalence of ADEs among adults receiving DTG-based regimens was 2.70% (95% CI: 1.98–3.68), with substantial heterogeneity across studies. Gastrointestinal and neuropsychiatric events were the most frequently reported adverse effects. Subgroup analyses showed significant variation by geographic region and study design, although heterogeneity remained high within subgroups. Evidence of publication bias was explored and adjusted where necessary. Interpretation: DTG-based regimens demonstrate overall good tolerability; however, clinically relevant gastrointestinal and neuropsychiatric adverse events persist and vary across settings. Standardized pharmacovigilance systems and routine monitoring particularly for vulnerable populations are essential to optimize long-term treatment safety and adherence.